Australian Public Assessment Report for Liraglutide

Unlike SGLT-2 inhibitors where there is a class effect, the long term safety study for lixisenatide showed non inferiority but not superiority for cardiovascular safety. This study had slightly different patient population (higher cardiovascular risk, younger, shorter duration diabetes, lower HbA1c), but also demonstrated a decrease in 0.4% ... ................
................